论文部分内容阅读
目的探讨醋酸甲地孕酮联合最佳支持疗法治疗晚期恶性肿瘤伴营养不足的临床疗效及安全性。方法晚期恶性肿瘤伴营养不足患者86例,随机分为治疗组及对照组,每组43例,分别接受最佳支持治疗联合醋酸甲地孕酮、最佳支持治疗,比较治疗后6周及12周体重、进食量及Karnofsky评分的变化情况,观察治疗组不良反应发生情况。结果用药6周及12周后,治疗组体重改变有效率均高于对照组(P<0.05);用药6周后,两组进食量改变及Karnofsky评分有效率比较,差异无统计学意义(P>0.05),但用药12周后,治疗组进食量改变及Karnofsky评分的有效率均高于对照组(P<0.05)。治疗组无严重不良事件发生。结论醋酸甲地孕酮联合最佳支持治疗对改善恶性肿瘤患者的营养状况有明确疗效。
Objective To investigate the clinical efficacy and safety of megestrol acetate combined with best supportive therapy in the treatment of advanced malignant tumors with nutritional deficiencies. Methods Totally 86 patients with malnutrition and malnutrition were randomly divided into treatment group and control group, with 43 cases in each group. The patients were given the best supportive therapy combined with megestrol acetate, the best supportive therapy, and the 6 weeks and 12 Week body weight, food intake and Karnofsky score changes observed in the treatment group adverse reactions. Results After 6 weeks and 12 weeks of treatment, the effective rate of body weight change in the treatment group was higher than that in the control group (P <0.05). After 6 weeks of treatment, the changes of food intake and Karnofsky score in the two groups showed no significant difference (P > 0.05). However, after 12 weeks of treatment, the change of food intake and the Karnofsky score of the treatment group were higher than those of the control group (P <0.05). The treatment group without serious adverse events. Conclusion Megestrol acetate combined with the best supportive treatment of patients with malignant tumors to improve the nutritional status of a clear effect.